Acumen Pharmaceuticals Inc (ABOS) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Acumen Pharmaceuticals Inc $0.97, price $2.31, upside -57.9%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Acumen Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.9010 – $20.28 · fair‑value band $0.6400 – $1.21 · the $2.31 price screens above the $0.9700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Acumen Pharmaceuticals in your weekly email
Every Wednesday you see whether Acumen Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc.
Show more
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Stock analysis
Acumen Pharmaceuticals Inc (ABOS) currently trades at $2.31, while our model-based Fair Value estimate is $0.9700, implying the stock looks roughly 137.6% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.6400 (bear) to $1.21 (bull), the price of $2.31 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Acumen Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $1.4M in FY2021. Reported net income was −$121M in FY2025.
Key figures
Market cap $169M · EPS (TTM) $−1.85 · Return on equity −93.2% · Return on assets (EBIT) −39.9% · Revenue (TTM) $329K · Free cash flow −$116M · Net cash $22.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 87% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −58%, ABOS screens richer than that median.
Fair Value models
Bear $0.6400Fair Value $0.9700Bull $1.21
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Acumen Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside−58% · Below median
Profitability
Return on assets−42% · Bottom 25%
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.40× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)84· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Acumen Pharmaceuticals Inc (ABOS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.9700 versus a price of $2.31, about −58% upside (overvalued).
What is the fair value of ABOS?
Our model-based fair value for Acumen Pharmaceuticals Inc is $0.9700 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.31.
What is the quality score of ABOS?
Acumen Pharmaceuticals Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acumen Pharmaceuticals Inc (ABOS)?
Our model-based price target is the fair value of $0.9700 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.6400, optimistic scenario $1.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Acumen Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.9700, about −58% upside versus a price of $2.31 (overvalued). Cautious scenario $0.6400, optimistic scenario $1.21. The calculation is refreshed regularly with new filings.
What is the revenue of Acumen Pharmaceuticals Inc (ABOS)?
Acumen Pharmaceuticals Inc reported trailing-twelve-month revenue of about $329K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Acumen Pharmaceuticals Inc (ABOS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acumen Pharmaceuticals Inc it is $0.9700 per share (as of Sep 23, 2026), against a price of $2.31. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Acumen Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ABOS trades above its calculated fair value: price $2.31, fair value $0.9700, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABOS?
No. The price is what the market pays today ($2.31); the fair value is what the company's own numbers justify ($0.9700). For Acumen Pharmaceuticals Inc the two are $1.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acumen Pharmaceuticals Inc worth?
The market values Acumen Pharmaceuticals Inc at about $169M (market capitalisation, as of Sep 23, 2026). Per share that is $2.31; our models calculate a fair value of $0.9700 per share.
What do the bullish and bearish scenarios say about ABOS?
Our models span a range for Acumen Pharmaceuticals Inc: cautious scenario $0.6400, base $0.9700, optimistic $1.21 per share (as of Sep 23, 2026, price $2.31). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acumen Pharmaceuticals Inc (ABOS)?
Balance-sheet figures for Acumen Pharmaceuticals Inc (as of Sep 23, 2026): return on equity −93.2%, debt of 0.32 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ABOS from its 52-week high?
Acumen Pharmaceuticals Inc trades at $2.31, about 32% below its 52-week high of $3.37 and 87% above the low of $1.23 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9700 is for.
Which stocks are comparable to Acumen Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acumen Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $2.31, calculated fair value $0.9700 (−58%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABOS calculated?
We run Acumen Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Acumen Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acumen Pharmaceuticals Inc (ABOS)?
The closing price on Sep 23, 2026 was $2.31. Our model-based fair value is $0.9700, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acumen Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($1.21). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.6400 to $1.21) leaves room in how you read the outcome.
Key figures of Acumen Pharmaceuticals Inc
How large is the market capitalisation of Acumen Pharmaceuticals Inc (ABOS)?
The market capitalisation of Acumen Pharmaceuticals Inc is $169M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Acumen Pharmaceuticals Inc (ABOS)?
Earnings per share at Acumen Pharmaceuticals Inc are $−1.85. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Acumen Pharmaceuticals Inc (ABOS)?
The return on equity (ROE) of Acumen Pharmaceuticals Inc is −93.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acumen Pharmaceuticals Inc (ABOS)?
On an EBIT basis the return on assets of Acumen Pharmaceuticals Inc is −39.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Acumen Pharmaceuticals Inc (ABOS) generate?
The free cash flow of Acumen Pharmaceuticals Inc is −$116M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acumen Pharmaceuticals Inc (ABOS) hold?
Acumen Pharmaceuticals Inc holds more cash than debt, $22.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Acumen Pharmaceuticals Inc in the live analysis
One click puts Acumen Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026